In the News

First Patient

First subject with profound vision loss due to AMD is treated in Melbourne, Australia with the use of OcuDyne’s OPTiC System in the hands of Ronil Chandra, MD and his team at Monash Health, as part of Phase I of the OC-1901 protocol.

First Study

Enrollment finally reopens in Melbourne, Australia for the OC-1901 study!

COVID Impact

Enrollment is halted in Melbourne, Australia due to the COVID-19 global pandemic as Australia goes into lock-down. 

Australia CHO Restrictions | 02 April 2020

Australian Study Approved

Protocol OC-1901 obtains Human Research Ethics Committee (HREC) approval to proceed in Melbourne, Australia. Enrollment opens at Centre for Eye Research Australia and Monash Health, two world renowned research facilities!

Clinical study details and site contacts can be located here: OC-1901 Australia | ANZCTR Listing